Spyre CEO Claims SPY001 Shows Best-in-Class Potential in IBD
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2026
0mins
"With our first Phase 2 readout of the year supporting a potential best-in-class profile for SPY001 in IBD, we have begun to deliver on the promise of what we believe is one of the most ambitious and differentiated pipelines in our industry. This result opened the possibility that our monotherapies could become valuable products in IBD and further strengthened our conviction that our combination therapies have the potential to deliver paradigm-changing efficacy for the more than two million Americans suffering from IBD," said Cameron Turtle, Chief Executive Officer of Spyre. "We have now begun enrolling our IBD combination therapies across the world and look forward to unveiling additional monotherapy results over the next few months and combination data next year. Outside IBD, we are advancing a potentially first- and best-in-class anti-TL1A antibody across multiple rheumatic diseases, where we continue to execute ahead of schedule and see significant opportunity for this mechanism paired with a convenient dosing profile. Collectively, we believe our assets, strategy, and execution position Spyre to deliver meaningful outcomes for patients and substantial long-term value for shareholders."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYRE
Wall Street analysts forecast SYRE stock price to fall
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 71.920
Low
40.00
Averages
56.67
High
70.00
Current: 71.920
Low
40.00
Averages
56.67
High
70.00
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HighVista Strategies Cuts Stake in Viridian Therapeutics by $7 Million
- Stake Reduction Details: HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics in its SEC filing dated May 15, 2026, representing an estimated $7.08 million trade, indicating a cautious outlook on the company's future performance.
- Impact of Stock Price Fluctuations: Despite Viridian Therapeutics' stock price rising 35% over the past year, the value of its position declined by $8.97 million at quarter-end, reflecting market concerns regarding the upcoming FDA decision.
- Company Financial Overview: Viridian's latest financial report indicates a revenue of $70.85 million and a net loss of $342.6 million over the trailing twelve months, highlighting the financial pressures faced during its development phase, which may affect investor confidence.
- Market Outlook and Challenges: With an FDA decision looming on June 30 for its lead therapy, Viridian's market performance may be impacted, especially after its Phase 3 clinical data fell short of expectations, prompting investors to carefully assess risks and opportunities.
See More
Spyre Therapeutics Q1 Earnings Miss Expectations Amid $403M Stock Offering
- Earnings Report Miss: Spyre Therapeutics reported a Q1 GAAP EPS of -$0.74, missing expectations by $0.05, indicating challenges in profitability that could affect investor confidence.
- Strong Cash Reserves: As of March 31, 2026, the company holds $1.2 billion in cash, cash equivalents, and marketable securities, with an expected runway into the second half of 2029, ensuring ongoing support for R&D and operations.
- Successful Stock Offering: Spyre Therapeutics completed a $403 million stock offering, exceeding its initial $300 million goal, providing additional funding that may be directed towards future clinical trials and product development.
- Clinical Trial Progress: The company announced topline results for SPY001 from the SKYLINE trial targeting moderate-to-severe ulcerative colitis, and while the earnings report was disappointing, positive clinical data may bolster future market performance.
See More
Spyre Therapeutics (SYRE.US) Officer Plans to Sell $5.83 Million in Common Stock via Form 144
Share Sale Announcement: Sheldon Sloan plans to sell 78,333 shares of Spyre Therapeutics (SYRE.US) on May 1, with an estimated market value of approximately $5.83 million.
Reduction in Holdings: Since April 1, 2026, Sheldon Sloan has reduced his shareholding in Spyre Therapeutics by 7,958 shares, valued at around $397.9K.
See More
Spyre Therapeutics Grants Stock Options to Employees
- Stock Option Grant: On May 1, 2026, Spyre Therapeutics approved the grant of stock options totaling 20,800 shares to four non-executive employees as equity inducement awards under the 2018 Equity Inducement Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biotechnology sector.
- Option Terms: The stock options have an exercise price of $69.42 per share, in compliance with Nasdaq listing rules, with a 10-year term; employees can exercise one-fourth of the options on their first anniversary and one-fortieth monthly thereafter, ensuring alignment of employee tenure with company growth.
- Strategic Implications: By implementing stock option incentives, Spyre not only enhances employee loyalty and commitment but also fosters innovation and development in the fields of inflammatory bowel disease and rheumatic diseases through performance-linked incentives.
- Company Overview: Spyre Therapeutics focuses on developing long-acting antibodies and combinations to redefine treatment standards for inflammatory bowel disease and rheumatic diseases, with a pipeline that includes investigational antibodies targeting α4β7, TL1A, and IL-23, indicating strong market potential.
See More
Spyre Therapeutics Prices Public Offering at $62 per Share
- Offering Size: Spyre Therapeutics has priced its public offering at $62.00 per share for 6.50 million shares, expecting gross proceeds of approximately $403 million, which will significantly bolster its funding for developing next-generation treatments for immune-mediated diseases.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, reflecting strong market confidence in Spyre and support for its future growth prospects.
- Stock Performance: SYRE has traded between $12.04 and $75.00 over the past year, closing at $64.01, and despite a 1.97% decline in after-hours trading, the overall performance indicates positive investor sentiment.
- Research Pipeline: Spyre's pipeline includes investigational extended half-life antibodies such as SPY001, SPY002, SPY003, and SPY072, with combination programs that will further drive innovation in treating inflammatory bowel disease, enhancing its competitive position in the market.
See More
Spyre Therapeutics Upsizes Public Offering to Raise $403 Million
- Upsized Offering: Spyre Therapeutics has announced an upsized public offering of 6.5 million shares at $62.00 each, aiming to raise approximately $403 million, exceeding the initial target of $300 million, indicating strong market demand for its stock.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional $60.5 million in shares at the same price, providing the company with potential for further capital infusion and enhancing its financial flexibility.
- Expected Closing Date: The offering is expected to close around April 16, 2026, allowing the company ample time to optimize the use of funds to support future research and market expansion initiatives.
- Positive Market Sentiment: The strong data from Spyre Therapeutics and upcoming clinical trial results provide a favorable backdrop for this offering, likely boosting investor confidence and driving the company's stock price upward.
See More
HighVista Strategies Cuts Stake in Viridian Therapeutics by $7 Million
- Stake Reduction Details: HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics in its SEC filing dated May 15, 2026, representing an estimated $7.08 million trade, indicating a cautious outlook on the company's future performance.
- Impact of Stock Price Fluctuations: Despite Viridian Therapeutics' stock price rising 35% over the past year, the value of its position declined by $8.97 million at quarter-end, reflecting market concerns regarding the upcoming FDA decision.
- Company Financial Overview: Viridian's latest financial report indicates a revenue of $70.85 million and a net loss of $342.6 million over the trailing twelve months, highlighting the financial pressures faced during its development phase, which may affect investor confidence.
- Market Outlook and Challenges: With an FDA decision looming on June 30 for its lead therapy, Viridian's market performance may be impacted, especially after its Phase 3 clinical data fell short of expectations, prompting investors to carefully assess risks and opportunities.
See More
Spyre Therapeutics Q1 Earnings Miss Expectations Amid $403M Stock Offering
- Earnings Report Miss: Spyre Therapeutics reported a Q1 GAAP EPS of -$0.74, missing expectations by $0.05, indicating challenges in profitability that could affect investor confidence.
- Strong Cash Reserves: As of March 31, 2026, the company holds $1.2 billion in cash, cash equivalents, and marketable securities, with an expected runway into the second half of 2029, ensuring ongoing support for R&D and operations.
- Successful Stock Offering: Spyre Therapeutics completed a $403 million stock offering, exceeding its initial $300 million goal, providing additional funding that may be directed towards future clinical trials and product development.
- Clinical Trial Progress: The company announced topline results for SPY001 from the SKYLINE trial targeting moderate-to-severe ulcerative colitis, and while the earnings report was disappointing, positive clinical data may bolster future market performance.
See More
Spyre Therapeutics (SYRE.US) Officer Plans to Sell $5.83 Million in Common Stock via Form 144
Share Sale Announcement: Sheldon Sloan plans to sell 78,333 shares of Spyre Therapeutics (SYRE.US) on May 1, with an estimated market value of approximately $5.83 million.
Reduction in Holdings: Since April 1, 2026, Sheldon Sloan has reduced his shareholding in Spyre Therapeutics by 7,958 shares, valued at around $397.9K.
See More
Spyre Therapeutics Grants Stock Options to Employees
- Stock Option Grant: On May 1, 2026, Spyre Therapeutics approved the grant of stock options totaling 20,800 shares to four non-executive employees as equity inducement awards under the 2018 Equity Inducement Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biotechnology sector.
- Option Terms: The stock options have an exercise price of $69.42 per share, in compliance with Nasdaq listing rules, with a 10-year term; employees can exercise one-fourth of the options on their first anniversary and one-fortieth monthly thereafter, ensuring alignment of employee tenure with company growth.
- Strategic Implications: By implementing stock option incentives, Spyre not only enhances employee loyalty and commitment but also fosters innovation and development in the fields of inflammatory bowel disease and rheumatic diseases through performance-linked incentives.
- Company Overview: Spyre Therapeutics focuses on developing long-acting antibodies and combinations to redefine treatment standards for inflammatory bowel disease and rheumatic diseases, with a pipeline that includes investigational antibodies targeting α4β7, TL1A, and IL-23, indicating strong market potential.
See More
Spyre Therapeutics Prices Public Offering at $62 per Share
- Offering Size: Spyre Therapeutics has priced its public offering at $62.00 per share for 6.50 million shares, expecting gross proceeds of approximately $403 million, which will significantly bolster its funding for developing next-generation treatments for immune-mediated diseases.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, reflecting strong market confidence in Spyre and support for its future growth prospects.
- Stock Performance: SYRE has traded between $12.04 and $75.00 over the past year, closing at $64.01, and despite a 1.97% decline in after-hours trading, the overall performance indicates positive investor sentiment.
- Research Pipeline: Spyre's pipeline includes investigational extended half-life antibodies such as SPY001, SPY002, SPY003, and SPY072, with combination programs that will further drive innovation in treating inflammatory bowel disease, enhancing its competitive position in the market.
See More
Spyre Therapeutics Upsizes Public Offering to Raise $403 Million
- Upsized Offering: Spyre Therapeutics has announced an upsized public offering of 6.5 million shares at $62.00 each, aiming to raise approximately $403 million, exceeding the initial target of $300 million, indicating strong market demand for its stock.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional $60.5 million in shares at the same price, providing the company with potential for further capital infusion and enhancing its financial flexibility.
- Expected Closing Date: The offering is expected to close around April 16, 2026, allowing the company ample time to optimize the use of funds to support future research and market expansion initiatives.
- Positive Market Sentiment: The strong data from Spyre Therapeutics and upcoming clinical trial results provide a favorable backdrop for this offering, likely boosting investor confidence and driving the company's stock price upward.
See More
